Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

Open access
Fu, Lei-lei, Tian, Mao, Li, Xiang, Li, Jing-jing, Huang, Jian, Ouyang, Liang, Zhang, Yonghui, Liu, Bo · 2015 · Oncotarget

Abstract

// Lei-lei Fu 1,* , Mao Tian 1,* , Xiang Li 1,* , Jing-jing Li 1 , Jian Huang 2 , Liang Ouyang 1 , Yonghui Zhang 1,3 and Bo Liu 1 1 State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, Department of Urology, West China Hospital, Sichuan University, Chengdu, China 2 School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China 3 Collaborative Innovation Center for Biotherapy, Department of Pharmacology & Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing, China * These authors contributed equally to this work Correspondence to: Bo Liu, email: // Jian Huang, email: // Keywords : bromodomain, BRD2/4, BRD3, BRDT, BET inhibitor Received : January 22, 2015 Accepted : February 13, 2015 Published : March 12, 2015 Abstract As a conserved protein interaction module that recognizes and binds to acetylated lysine, bromodomain (BRD) contains a deep, largely hydrophobic acetyl lysine binding site. Proteins that share the feature of containing two BRDs and an extra-terminal domain belong to BET family, including BRD2, BRD3, BRD4 and BRDT. BET family proteins perform transcription regulatory function under normal conditions, while in cancer, they regulate transcription of several oncogenes, such as c-Myc and Bcl-2. Thus, targeting BET proteins may be a promising strategy, and intense interest of BET proteins has fueled the development of structure-based bromodomain inhibitors in cancer. In this review, we focus on summarizing several small-molecule BET inhibitors and their relevant anti-tumor mechanisms, which would provide a clue for exploiting new targeted BET inhibitors in the future cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.3551

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 221

Metadata

Authors
Fu, L.-L., Tian, M., Li, X., Li, J.-J., Huang, J., Ouyang, L., Zhang, Y., & Liu, B.
Venue
Oncotarget
Published
2015-03-12
Volume
6
Issue
8
Pages
5501-5516
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1850786313
Cited by
221
References
11
FWCI
12.87
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.